Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme

被引：0
|
作者：
Vermeire, S. [1 ]
Rubin, D. T. [2 ]
Regueiro, M. D. [3 ]
Takeuchi, K. [4 ]
Walsh, A. [5 ]
Kotze, P. G. [6 ]
Charabaty, A. [7 ]
Goetsch, M. [8 ]
Lazin, K. [8 ]
Wu, J. [9 ]
Tsamos, G. [10 ]
Segovia, M. [11 ]
Branquinho, D. [11 ]
Danese, S. [12 ,13 ]
机构：
[1] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[2] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[3] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH USA
[4] Tsujinaka Hosp Kashiwanoha, IBD Ctr, Dept Gastroenterol, Kashiwa, Chiba, Japan
[5] Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England
[6] Pontificia Univ Catolica Parana PUCPR, IBD Outpatient Clin, Colorectal Surg Unit, Curitiba, Brazil
[7] Johns Hopkins Sch Med, Div Gastroenterol & Hepatol, Washington, DC USA
[8] Pfizer AG, Zurich, Switzerland
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Thessaloniki, Thessaloniki, Cent Macedonia, Greece
[11] Pfizer Inc, New York, NY USA
[12] IRCCS San Raffaele Hosp, Milan, Italy
[13] Univ Vita Salute San Raffaele, Div Gastroenterol & Endoscopy, Milan, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0057
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP018
引用
收藏
页码：i115 / i117
页数：3
相关论文
共 50 条
  • [31] Efficacy and safety outcomes up to ∼4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study
    Feagan, B. G.
    Matsuoka, K.
    Rogler, G.
    Faes, M.
    Oortwijn, A.
    de Haas, A.
    Rudolph, C.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I47 - I49
  • [32] LONG-TERM SAFETY OF ABATACEPT: INTEGRATED ANALYSIS OF CLINICAL PROGRAMME DATA OF UP TO SEVEN YEARS OF TREATMENT
    Hochberg, Marc
    Westhovens, Rene
    Aranda, Richard
    Kelly, Sheila
    Khan, Nadar
    Qi, Keqin
    Pappu, Ramesh
    Delaet, Ingrid
    Luo, Allison
    Torbeyns, Anne
    Moreland, Larry
    Cohen, Roger
    Gujrathi, Sheila
    Weinblatt, Michael
    RHEUMATOLOGY, 2011, 50 : 124 - 124
  • [33] Efficacy and safety outcomes up to ∼4 years of treatment with filgotinib 200mg among SELECTIONLTE patients with ulcerative colitis
    Arnott, Ian
    Feagan, Brian
    Matsuoka, Katsuyoshi
    Rogler, Gerhard
    Faes, Margaux
    Oortwijn, Alessandra
    de Haas, Angela
    Rudolph, Christine
    Peyrin-Biroulet, Laurent
    GUT, 2023, 72 (SUPPL_2) : A39 - A40
  • [34] Adalimumab maintains remission for up to 4 years in patients with ulcerative colitis
    Colombel, J. -F.
    Sandborn, W. J.
    Ghosh, S.
    Wolf, D.
    Panaccione, R.
    Feagan, B.
    Reinisch, W.
    Robinson, A. M.
    Lazar, A.
    Kron, M.
    Huang, B.
    Thakkar, R. B.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S306 - S306
  • [35] Adalimumab Maintains Remission for Up to 4 Years in Patients With Ulcerative Colitis
    Colombel, Jean-Frederic
    Sandborn, William
    Ghosh, Subrata
    Wolf, Douglas C.
    Panaccione, Remo
    Feagan, Brian G.
    Reinisch, Walter
    Robinson, Anne
    Lazar, Andreas
    Kron, Martina
    Huang, Bidan
    Thakkar, Roopal
    GASTROENTEROLOGY, 2014, 146 (05) : S589 - S590
  • [36] Efficacy and Safety of Etrasimod in Patients With Ulcerative Colitis Stratified by Body Mass Index: A Post Hoc Analysis From the ELEVATE UC Clinical Program
    Yarur, Andres J.
    Long, Millie D.
    Torres, Joana
    Nandi, Neilanjan
    Cross, Raymond K.
    Abbatemarco, Arcangelo M.
    Blanco, David
    Niezychowski, Wojciech
    Crosby, Catherine M.
    Wu, Joseph
    Pradeep, Gokul
    Goetsch, Martina
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1026 - S1027
  • [37] Etrasimod efficacy in patients with mildly to moderately active Ulcerative Colitis (modified Mayo score 4-6) in the phase 3 ELEVATE UC clinical programme
    Yarur, A. J.
    D'Haens, G. R.
    Baert, F.
    Goetsch, M.
    Zang, C.
    Gu, G.
    Mazur, R.
    Keating, M.
    Kudlacz, E.
    Sidhu, S.
    Wosik, K.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1460 - i1462
  • [38] Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials
    Takeuchi, Ken
    Hisamatsu, Tadakazu
    Nakase, Hiroshi
    Matsuoka, Katsuyoshi
    Keating, Michael
    Yuasa, Hirotoshi
    Oe, Motoki
    Arai, Shoko
    Mazur, Rafal
    Hibi, Toshifumi
    DIGESTION, 2024,
  • [39] ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF INFECTION RATES FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 CLINICAL TRIALS
    Regueiro, Miguel D.
    Siegmund, Britta
    Yarur, Andres J.
    Steinwurz, Flavio
    Gecse, Krisztina
    Goetsch, Martina
    Bhattacharjee, Abhishek
    Wu, Joseph
    Green, Jesse
    McDonnell, Aoibhinn
    Crosby, Catherine
    Lazin, Krisztina
    Branquinho, Diogo
    Modesto, Irene
    Abreu, Maria T.
    GASTROENTEROLOGY, 2023, 164 (06) : S1105 - S1106
  • [40] The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of post-marketing data
    Russell, Cohen D.
    Fatima, Bhayat
    Aimee, Blake
    Simon, Travis
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S4 - S4
12345